Company news
Ascentage Pharma Group International (HKEX:6855) news
Every Ascentage Pharma Group International press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
August 5, 2026
Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
August 5, 2026
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
July 26, 2026
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
June 14, 2026
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
May 31, 2026
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
May 31, 2026
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
May 31, 2026
Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress
May 12, 2026
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026
April 21, 2026
Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Associati...
April 19, 2026
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
March 25, 2026
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AAC...
March 17, 2026
Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026
March 11, 2026
Ascentage Pharma to Participate in Three Upcoming Investor Conferences
February 23, 2026
Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
February 9, 2026
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288
February 5, 2026
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference
January 14, 2026
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
January 6, 2026
Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Different...
December 8, 2025
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
December 8, 2025
ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Be...
December 8, 2025
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patient...
December 7, 2025
Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (...
December 6, 2025
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA a...
December 4, 2025
Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025
December 1, 2025
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal T...
November 24, 2025
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025
November 19, 2025
Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025
November 3, 2025
Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025
November 3, 2025
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025
October 29, 2025
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025
October 7, 2025
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025
August 25, 2025
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates
August 20, 2025
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Mye...
August 17, 2025
Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025
August 7, 2025
Ascentage Pharma to Participate in Evercore China Biotech Summit
August 1, 2025
Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025
July 23, 2025
Ascentage Pharma Announces Pricing of Top-Up Placement
July 14, 2025
Ascentage Pharma Announces Proposed Top-Up Placement
July 14, 2025
Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL
July 10, 2025
Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Developme...
July 7, 2025
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
June 15, 2025
Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hemato...
June 9, 2025
Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Re...
June 2, 2025
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
June 2, 2025
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected fo...
May 22, 2025
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Hi...
April 28, 2025
Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lis...
April 23, 2025